Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amgen Inc Market Cap
Based on ratings from 32 stock analysts, the Amgen Inc stock price is expected to increase by 19.09% in 12 months. This is calculated by using the average 12-month stock price forecast for Amgen Inc. The lowest target is $195 and the highest is $405. Please note analyst price targets are not guaranteed and could be missed completely.
About 32 Wall Street analysts have assignedAMGN 14 buy ratings, 16 hold ratings, and 2 sell ratings. This means that analysts expect Amgen Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AMGN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Gregory Renza RBC Capital | Outperform | $330 | Maintains | Nov 27, 2024 |
| Tim Anderson Wolfe Research | Peer Perform | Initiates | Nov 15, 2024 | |
| Geoff Meacham Citigroup | Neutral | $335 | Initiates | Nov 14, 2024 |
| Michael Yee Jefferies | Buy | $380 | Maintains | Nov 12, 2024 |
| Colin Bristow UBS | Neutral | $326 | Maintains | Oct 31, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $405 | Reiterates | Oct 22, 2024 |
| Yaron Weber TD Cowen | Buy | $383 | Maintains | Oct 21, 2024 |
| Aaron Gal Bernstein | Outperform | $380 | Initiates | Oct 17, 2024 |
| Robyn Karnauskas Truist Securities | Hold | $333 | Downgrade | Oct 14, 2024 |
| Carter Gould Barclays | Equal-Weight | $315 | Maintains | Oct 7, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $405 | Initiates | Sep 27, 2024 |
| Gregory Renza RBC Capital | Outperform | $362 | Reiterates | Sep 26, 2024 |
| Brian Skorney Baird | Underperform | $215 | Reiterates | Sep 25, 2024 |
| Gregory Renza RBC Capital | Outperform | $362 | Maintains | Aug 7, 2024 |
| Mohit Bansal Wells Fargo | Equal-Weight | $335 | Downgrade | Aug 7, 2024 |
| Jay Olson Oppenheimer | Outperform | $380 | Maintains | Aug 7, 2024 |
| James Shin Deutsche Bank | Hold | $305 | Reiterates | Aug 7, 2024 |
| Yaron Weber TD Cowen | Buy | $381 | Maintains | Aug 7, 2024 |
| Geoff Meacham B of A Securities | Neutral | $330 | Maintains | Aug 7, 2024 |
| Terence Flynn Morgan Stanley | Equal-Weight | $303 | Maintains | Jul 11, 2024 |
When did it IPO
1984
Staff Count
26,700
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - General
CEO
Mr. Robert A. Bradway
Market Cap
$146.52B
In 2023, AMGN generated $28.19B in revenue, which was a increase of 7.09% from the previous year. This can be seen as a signal that AMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 07 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Amgen's Phase 3 study shows that adding BLINCYTO® to chemotherapy improves three-year disease-free survival to 96% in pediatric patients with standard risk B-cell ALL.
Why It Matters - Positive Phase 3 results for BLINCYTO® suggest strong market potential and improved outcomes in pediatric cancer treatment, potentially boosting Amgen's revenue and stock performance.
Sat, 07 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - The "Dogs of the Dow" refers to the highest-yielding stocks in the Dow Jones Industrial Average. Investors should assess whether these stocks are undervalued or facing potential risks.
Why It Matters - The "Dogs of the Dow" strategy highlights high-yield stocks that may signal undervaluation or risk. Investors need to assess underlying reasons for price drops to make informed choices.
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Dividend-paying stocks can provide steady passive income and may help investors outperform the S&P 500 index.
Why It Matters - Dividend-paying stocks can provide consistent income and potentially outperform the S&P 500, appealing to income-focused investors and those seeking stability in their portfolios.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Amgen will invest $1 billion to establish a second drug substance manufacturing facility in North Carolina, enhancing its production capabilities.
Why It Matters - Amgen's $1 billion investment in North Carolina signals growth and expansion, potentially boosting revenue and market position, which may positively impact stock performance.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - CNBC
Summary - Amgen's weight loss injection, MariTde, is under scrutiny by Wall Street. Additionally, GE HealthCare plans to acquire a Japanese drug company.
Why It Matters - Amgen's weight loss injection could impact its revenue growth and market share, while GE HealthCare's acquisition may enhance its product portfolio and competitive positioning.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - When the Federal Reserve indicates monetary easing, investors typically favor stable, high-yield dividend stocks for income and growth potential.
Why It Matters - Rising interest rates often lead to a shift in investor preference towards dividend stocks, impacting their demand and prices, which can influence overall market dynamics.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
